SEC Filing Summary
Issuer and period: The filing is a Form 10-K for Marika Inc., a Nevada development-stage company, for the fiscal year ended June 30, 2014. This differs from the request metadata, which names Pavella Therapeutics, Inc. and specifies 2013 Q4. The filing does not provide a clear match to that metadata.
Business context
Marika proposed an online errand and concierge marketplace that would connect customers posting tasks with agents bidding to perform them; its planned commission was 20%. The company reported no business operations or revenue. It said insufficient funding had prevented execution of its business plan and that it was discussing alternative directions with third parties, but had signed no definitive agreement as of the filing.
Financial results and position
| Metric | FY ended June 30, 2014 | Comparable period |
|---|---|---|
| Revenue | $0 | $0 in May 24–June 30, 2013 |
| Net loss | $15,712 | $274 in May 24–June 30, 2013 |
| Operating expenses | $15,712, including $15,187 professional fees | $274 |
| Cash and total assets | $11,138 | $5,200 |
| Total liabilities | $1,124 | $474 |
| Stockholders’ equity | $10,014 | $4,726 |
| Financing cash inflow | $21,000, from common-stock issuance | $5,474: $5,000 stock proceeds and $474 director loan |
The filing reports no operating margin, since the company had no revenue. No interest or income taxes were paid. The director loan was $474, unsecured, non-interest-bearing, and due on demand. No credit lines or bank financing were available.
Cash-flow figures are inconsistent within the filing: the cash-flow statement reports $15,062 used in operating activities for FY2014, reflecting a $650 increase in accounts payable, while MD&A states $15,712. The cumulative operating-cash-flow figure also differs between these sections. The statement reports a $5,938 increase in cash for FY2014.
Changes, outlook and risks
- The net loss increased from $274 in the initial 2013 period to $15,712 in FY2014, primarily as professional fees were incurred; the company still generated no revenue.
- Management expected to rely on existing funds and further equity or debt issuances. It said available working capital and anticipated financing were expected to fund operations for six months, but also said further capital and revenue would be needed for long-term operations. Financing might not be available on acceptable terms, and equity or convertible debt could dilute shareholders.
- The auditor’s report expressed substantial doubt about the company’s ability to continue as a going concern, citing operating losses, working-capital concerns, and the need for new capital. The financial statements include no adjustments for the possible outcome.
- Management identified material weaknesses in internal control over financial reporting: no independent audit committee oversight, inadequate cash controls and segregation of duties, and no formal data-backup or off-site-storage procedures.
- The company had one officer and director, no other employees, no established active trading market, and no shares traded as of June 30, 2014. No dividends were paid or expected in the foreseeable future.
- The filing reports no material commitments, off-balance-sheet arrangements, or pending legal proceedings.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied metadata identifies a different company and period than the filing.
- Reconcile the operating cash-flow figures between MD&A and the audited cash-flow statement.
- Assess the company’s ability to raise capital, fund operations, and continue as a going concern.
- Track whether the proposed business was launched or whether the company entered into a definitive agreement to change direction.
- Review remediation of the disclosed internal-control material weaknesses and the lack of an active trading market.